The loan deal is actually pretty good. If you read the terms, 2/3 of it will not be available to DSCO until they actually start selling Surfaxin. At that point, I'm not worried about dilution because the product will be on the market and revenue--no matter how paltry--will be coming in. I also believe that the actual initiation of selling will spark investor confidence and we will see the stock move up. It's not so much because of the revenue--we all know that the revenue stream for Surfaxin liquid is relatively modest--it's symbolic. That is to say, the product is finally on the market, that by-and-large paves the way for introduction of LS and Aerosurf.
I do agree, however, that Cooper is a complete loser and he needs to go. I'm not sure who is worse: Amick or Cooper. At least Amick had ties to J&J and had decades of experience.